Home › Medical › Gender dysphoria
Gender dysphoria
Gender dysphoria is the clinical term for the persistent distress that arises when someone feels uncomfortable with their own body or with the social role attached to their observed sex. That distress is real and can be severe. How it arises and which treatment actually helps is scientifically far less clear than is often suggested in public information.
What is gender dysphoria?
The term was introduced in 2013 in the DSM-5 to replace 'gender identity disorder'. The shift was mainly conceptual: the identity itself was no longer considered a disorder, the distress was. That distress can manifest as aversion to one's own bodily features, a strong wish to live as the other sex, and social discomfort. Severity varies widely, from mild dissatisfaction to severe psychological suffering.
Important: gender dysphoria is a diagnosis on the basis of self-report and behavioural observation. There is no objective biological marker. That distinguishes it from, for instance, an endocrine condition and has consequences for how solid the diagnosis is.
Diagnostic criteria
The DSM-5 requires a clear and persistent difference between experienced and observed sex, for at least six months, with clinically significant distress or functional impairment. For children, additional criteria apply. In practice, however, diagnosis depends strongly on the clinician's interpretation, and in modern gender clinics the criteria have often been applied more loosely than originally intended.
The WHO's ICD-11 deliberately removed 'gender variation' (gender incongruence) from the mental-disorders chapter. Critics point out that this depathologisation is mainly a political movement and is separate from the question of whether early medical intervention is justified.
Changed population
Until about 2010, gender dysphoria mainly involved young children — often boys — with an early, persistent dysphoria. Since around 2012 the picture has changed drastically: in countries such as the Netherlands, the UK and Sweden, a rapidly growing number of adolescents now present, with a striking overrepresentation of girls and high psychiatric comorbidity (autism, anxiety, depression, trauma). This population is not the population on which the original Dutch Protocol was based.
Treatment and the evidence gap
Treatment options range from psychological support and social transition to hormone therapy and surgery. The Cass Review (2024) concluded after systematic investigation that the evidence base for medical interventions in young people is weak. The Swedish SBU (2022), the Finnish COHERE and the Danish Sundhedsstyrelsen drew comparable conclusions. These countries have substantially tightened their practice; the Netherlands has (not yet) done so.
For adults the evidence for positive outcomes at the group level is somewhat stronger, but here too long-term studies are scarce and poorly controlled.
Desistance, social contagion and comorbidity
Research by Steensma et al. (2013) showed that a substantial proportion — in some cohorts more than 60% — of children with gender dysphoria lose the dysphoria during or after puberty. That phenomenon, desistance, is a central reason for caution with early medical intervention.
In addition there is debate about social factors in the sudden rise particularly among teenage girls after 2010. The concept of rapid-onset gender dysphoria, introduced by Littman (2018), is contested but points to a pattern seen in multiple countries: dysphoria that arises later in life, often in clusters of friends and with intensive social-media use. See also rapid-onset gender dysphoria.
The high rate of comorbidity raises the question whether dysphoria is sometimes an expression of underlying problems that require different treatment. A diagnosis of 'gender dysphoria' must not overshadow those other problems.